NewCardio, Inc.
OTC BB: NWCI
Corporate Headquarters
NewCardio, Inc.
2350 Mission College Blvd., Suite 1175
Santa Clara, CA 95054
Phone: 203-644-5200
Fax: 408-907-8923
www.newcardio.com
Investor Relations Contact
Jeff Stanlis
Hayden IR
11 Penn Plaza, 5th Floor, Suite 5090
New York, NY 10001
Phone: 602-476-1821
www.haydenir.com
jeff@haydenir.com
The foregoing compilation relates to NewCardio, Inc. and
contains forward-looking statements, which are made
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-
looking statements involve risks and uncertainties that
could cause actual results to differ materially from the
forward-looking statements. When used in this document,
the words "anticipate," "believe," "estimate," "expect" and
similar expressions as they relate to NewCardio or its
management, are intended to identify such forward-
looking statements. NewCardio’s actual results,
performance or achievements could differ materially from
the results expressed in, or implied by these forward-
looking statements. For more detailed information the
reader is referred to NewCardio’s Form 10-K and other
related documents filed with the Securities and Exchange
Commission. This does not constitute an offer to buy or
sell securities by the Company and is meant purely for
informational purposes. Hayden IR (HIR) its affiliates,
officers, directors, subsidiaries and agents have been
compensated by the Company for the creation of this
document. NewCardio and HIR have entered into a four-
year term effective February 8, 2008. HIR currently
receives $3,500 per month as well as 100,000 warrants
vesting 25,000 per year. HIR has relied upon information
received from the Company, which, although believed to
be reliable, cannot be guaranteed. This information is not
an endorsement of the Company by HIR. HIR is not
responsible for any claims made by the Company. You
should independently investigate and fully understand all
risks before investing.
Overview
NewCardio, Inc. (OTC BB: NWCI), a cardiac diagnostic
and services company, develops proprietary platform tech-
nology to dramatically improve accuracy and signifi-
cantly increase the diagnostic value of the standard 12-
lead electrocardiogram (ECG). NewCardio’s products
incorporate novel, state-of-the-art technology that manage-
ment believes will significantly improve the diagnostic
accuracy and precision of the analysis and use of signals
from ECGs, without disrupting the well-established 12-lead
ECG practice. The Company’s technology is based on a
three-dimensional approach to modeling cardiac activity
using standard 12-lead ECG signals. Accordingly, NewCar-
dio is poised to, over time, derive value from each of the
375 million ECGs performed annually around the world.
NewCardio is applying its proprietary technology to assess
cardiac safety of new drugs in development and to improve
clinical diagnosis and assessment of patients with sus-
pected and established heart disease. Management be-
lieves this technology represents a highly significant ad-
vance and has the opportunity to be a disruptive force in
markets that exceed $4.5 billion in aggregate annually.
NewCardio has several clinical studies in progress to vali-
date, further develop and refine its technology and prod-
ucts. The Company recently launched its lead product,
QTinno, and announced its first commercialization agree-
ments. Revenue is targeted from QTinno during early 2010.
The first commercial announcement was that a top-five
global pharmaceutical company selected QTinno as its
automated solution and would include this in RFPs for TQT
studies going forward. In addition, the Company has signed
Master Services Agreements (MSAs) with two major (top
five) CROs and a Dedicated Phase One unit.
NewCardio management includes thought leaders from the
semiconductor industry (Intel), pharmaceuticals, medical
devices (St. Jude Medical), Core Labs and the investment
industry. The Company believes its broad-based manage-
ment team is particularly well-suited to advance the Com-
pany’s goals and develop its technology into a set of es-
sential diagnostic tools for the ECG segment of the cardiac
diagnostics industry.
Market Opportunity
Key initial applications include cardiac toxicity (lethal ar-
rhythmias) determination during new drug development,
and cardiac status for
Corporate Facts
acute and chronic
(as of December 31, 2009)
patient management.
FY End: Dec. 31
The FDA requires that
all new drugs be Stock Price: $0.72
tested for potential 52-Week Range: $0.37-1.90
cardiac toxicity early in Shares Out: 42.5 M
development. Current
methods are costly Fully diluted: 59.0 M
and time-consuming. Mkt. Cap: $42.5 M
New drugs are often
tested on more than 1,000 subjects, with ECGs collected at
multiple time points. Using NewCardio’s 3D approach, drug
sponsors and CROs can automate this process, signifi-
cantly reducing the cost and accelerating the test
times for drugs in development. A leading independent
industry analyst estimated this market to exceed $650
million annually.
NewCardio’s products could change the way patients with
chronic heart conditions will monitor their disease outside
the acute care setting. The Company is developing a hand-
held device that could transmit the Visual ECG and synthe-
sized 12-lead data to doctors remotely. This will enable
complete cardiac assessment, in contrast to current de-
vices that enable arrhythmia monitoring only. A recent
study by Frost & Sullivan estimated this market to
approach $2 billion.
The Company believes its diagnostic tools will substantially
improve the accuracy and timeliness of the diagnosis and
response to patients arriving at Emergency Departments
with suspected acute coronary syndromes (heart attack
and related conditions). NewCardio’s Visual3Dx will enable
doctors to diagnose acute coronary syndromes more
quickly and accurately than with traditional methods, possi-
bly saving thousands of lives annually and reducing costs
associated with unnecessary hospital admissions. With
more than 70 million ECGs performed in ERs each year in
the U.S. alone at an average (current) reimbursement of
$30 each, this market could exceed $2 billion annually
at current reimbursement rates.
Additional applications include sports medicine, screening
and monitoring, significantly increasing the total market
opportunity for this innovative application.
January 2010
Investment Highlights

The Company’s technology uses the widely
accepted, standard 12-lead ECG input and
displays the signals in a three-dimensional
output, providing significantly increased
sensitivity accuracy and precision and the
capability to automate what has historically
used more costly and labor-intensive manual
or semi-automated processes.

The Company is developing three unique
solutions using its core platform technology,
addressing three distinct and rapidly growing
segments of the industry and creating
planned revenue diversity.

NewCardio’s first solution, QTinno™, offers
the first realistic opportunity for fully
automated testing in Thorough QT (TQT)
and cardiac safety clinical trials. The FDA
requires that all new drugs be tested (TQT)
for potential cardiac toxicity early in clinical
development. Current testing methods are
costly and time-consuming. Management
believes QTinno will significantly increase
accuracy and productivity of the cardiac
toxicity assessment.

The Company’s initial studies have
confirmed that QTinno delivers virtually
identical accuracy to the existing semi-
automated “gold standard”, but at far lower
cost and with fully automated tests
completed in hours, as compared to weeks
of labor-intensive manual review by
cardiologists when semi-automated
approaches are used.

The Company has assembled a team of
talented and experienced entrepreneurs and
business managers, including leaders from
various industries like technology, pharma,
academics, and a wide range of other
scientists and professionals. The Company’s
new chairman is the most-prolific inventor of
electrical medical devices in the world;
virtually every ICD (Implantable Defibrillator)
manufacturer licenses patents covering
technology invented by the chairman.
NewCardio’s 3D ECG Platform Technology
The electrocardiogram (ECG) is a proven clinical tool for diagnosis and treatment
of heart disease and it plays a critical role in determining the extent and severity
of cardiac issues. The ECG is the most common cardiovascular laboratory
procedure with as many as 375 million ECGs performed annually around the
world. The standard ECG is a
universally accepted diagnostic tool,
but it is not without significant
limitations. It lacks both sensitivity and
specificity, often failing to detect
significant cardiac disease and
alternatively suggesting significant
cardiac disease when the heart is
structurally sound.
The standard clinical ECG includes
recordings from 12 leads. “Pattern
recognition” is the most prevalent
method for ECG interpretation. The
observer reviews the findings of the 12
lead ECG and compares it to the range of expected findings in normal
NewCardio Solutions
NewCardio’s technology provides dramatically higher ECG sensitivity for emergency and real-time cardiac diagnostics
QTinno™
QTinno™ is a
software suite
that provides
automated,
comprehen-
sive analysis
of QT intervals
and other
ECG-based
cardiac safety
for the pharmaceutical industry and drug regu-
lators. Its key features include:
(1) full automation, with minimal to no human
intervention required, greatly improving
the productivity of the trial;
(2) accuracy and precision that the Company
believes is equal to the best manual
assessments;
(3) the ability to provide high-quality quantita-
tive data from a broad range of difficult-to-
read ECGs.
individuals. By associating abnormal ECGs with their corresponding heart
abnormalities, various cardiac diseases are associated with and identified from
certain ECG "patterns." However, the best readers of 12 lead ECGs are trying to,
based on the 12 waveforms, synthesize in their mind electrical activity of the
heart. The human mind is not able to accomplish this diagnostically critical step
and indeed synthesize three dimensional electrical activity of the heart.
NewCardio’s 3D ECG platform technology is a set of algorithms and tools that
provide a comprehensive method to describe cardiac electrical activity in time
and space, introducing modern computer and software-based technology create
a new and more diagnostically valuable and easy to read way of utilizing ECG
data. This 3D ECG technology extracts additional information from standard 12-
lead ECG signals and uses it to generate a 3D representation of cardiac
electrical activity as a function of time. To further enhance understanding and
interpretation, the program superimposes the diagnostically relevant electrical
information on an intuitive, revolving 3D anatomic model of the heart. The
Company believes this enables the 3D platform technology to detect potentially
fatal diseases such as acute coronary syndromes with far greater sensitivity and
specificity than is possible with the standard ECG.
CardioBip™ Visual3Dx™
The Visual3Dx™ is a
The CardioBip™
system is a unique clinical diagnostic tool
providing a comprehen-
solution to the prob-
lem of urgent ECG sive method to describe
cardiac electrical activity
telemonitoring,
capable of providing in time and 3D space. It
uses modern mathemati-
far more comprehensive and accurate transtele-
phonic ECG data than any other integrated device cal, computer and software-based technology
which enables the Visual3Dx:
currently in use which are capable of arrhythmia
(1) to extract key additional information from
monitoring only. It is comprised of a mobile ECG
standard 12-lead ECG signals and
recording and transmitting device, and a diagnos-
(2) to generate a 3D representation of car-
tic center which receives, processes and analyzes
the data. The unique data collected by the Car- diac electrical activity over time. In addi-
dioBip provides sufficient information to allow tion, the program superimposes the diag-
nostically relevant electrical information
accurate, immediate reconstruction of a complete
12-lead ECG from a calibrated, patient-specific on an intuitive, revolving 3-D anatomic
model of the heart, which further en-
transformation matrix. These features enable
more accurate and timely diagnoses of acute hances understanding and clinical inter-
pretation. Importantly, the Visual3Dx also
cardiac events, and facilitate immediate interven-
tion in life-threatening situations. The small form includes algorithms that “normalize” the
ECG input signal, insuring accurate and
factor and fully integrated electrodes without any
wires make this device an ideal candidate for the balanced representation of all heart re-
gions including remote, difficult-to-
integration with popular mobile phone/PDA plat-
forms. diagnose regions such as the posterior
Leadership and Advisors
Board of Directors
 Mark W. Kroll, PhD, FACC, FHRS, Chairman: the most-prolific
inventor of electrical medical devices in the world with over 260
U.S. patents. Served as Sr. VP & CTO for St. Jude Medical Inc.
Senior Management
 Branislav Vajdic, PhD, Co-Founder and Chief Executive Officer:
23-years of product development at Intel Corporation. Held
various senior management positions in Intel’s Pentium and Flash
memory divisions. Designed first Flash memory device for Intel.
Author of several key flash memory design patents.
 Vincent W. Renz, President: Joined NWCI from ClinPhone where
he served as COO. He previously worked for eResearch
Technology, Inc. as the Executive VP & CTO.
 Dorin Panescu, PhD, - Chief Technical Officer and VP of
Research and Development: Most recently served as Director,
Technology Development, for the Company’s Cardiac Rhythm
Management Division for St. Jude Medical, Inc., (NYSE: STJ).
Previously was VP of Research and Development, Operations
and Intellectual Property for Refractec, Inc.
 Ihor Gussak, MD, PhD, FACC - VP and Chief Medical Officer: A
world-recognized expert in electrocardiology and cardiac safety
with five years experience with eResearchTechnology, Inc., where
he served as VP of Global Medical Affairs. He has also worked
with leading pharmaceutical companies, serving as a senior
executive for Boehringer Ingelheim Pharmaceuticals and
previously as a key executive for Aventis Pharmaceuticals Inc.
 Richard D. Brounstein, CFO: Joined NWCI from Calypte
Biomedical Corporation, most recently as CFO. Served as CFO
for Certicom Corporation. From 1997 to 2000, he was CFO for
VidaMed, Inc., a medical device company. Previous experiences
include Arthur Andersen, as well as an appointment to the SEC
Advisory Committee on Smaller Public Companies.
 Kenneth Londoner, Senior Director, Business Development:
Proven history as an institutional money manager with J. & W.
Seligman & Co., Inc., and a co-Founder of Safe Ports, Inc.
 Joseph Esposito, Senior Business Advisor: President and CEO of
eResearchTechnology, Inc. (Nasdaq: ERES) from 2001 to 2006
and President and COO from 1998 until 2001.
Scientific Advisory Board
 Mark Josephson., MD., Chairman: Mark Josephson is the Herman
Dana Professor of Medicine at Harvard and Chairman of
Cardiology at Beth Israel Deaconess Medical Center in
Boston. He is credited with developing clinical cardiac
electrophysiology from an intellectual curiosity to a powerful tool
for the diagnosis and management of cardiac arrhythmias. He has
published more than 300 original publications and 200 chapters,
reviews and editorials. His textbook, Clinical Cardiac
Electrophysiology, is the fundamental textbook in the field.